Regarding the trials IMpower130 and IMpower150, we used the data in the intention-to-treat wild-type population, because these studies included patients with non-squamous NSCLC harboring epidermal growth factor receptor or anaplastic lymphoma kinase alterations [21, 27]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.